drugset / Trial / NCT01421134

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

NCT01421134

Phase 3 Completed 211 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Timeline

Start
2011-09
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg
Subject Lurasidone Small molecule 40 mg
Subject Lurasidone Small molecule 60 mg